Literature DB >> 21763203

Theoretical and experimental basis of oocyte vitrification.

Gary D Smith1, Eduardo E Motta, Paulo Serafini.   

Abstract

In the last decades significant advances have been made in successful cryopreservation of mammalian oocytes. Human oocyte cryopreservation has practical application in preserving fertility for individuals at risk of compromised egg quality due to cancer treatments or advanced maternal age. While oocyte cryopreservation success has increased over time, there is still room for improvement. Oocytes are susceptible to cryodamage; which collectively entails cellular damage caused by mechanical, chemical or thermal forces during the vitrification and warming process. This review will delineate many of the oocyte intracellular and extracellular structures that are/may be stressed and/or compromised during cryopreservation. This will be followed by a discussion of the theoretical basis of oocyte vitrification and warming, and a non-exhaustive review of current experimental data and clinical expectations of oocyte vitrification will be presented. Finally, a forward-thinking vision of a potential means of modifying and improving vitrification and warming procedures and success will be proposed. This review addresses theoretical and experimental evidence accumulated over the last two decades supporting the application of vitrification and warming to oocyte cryopreservation. Issues ranging from clinical needs for oocyte cryopreservation, cryopreservation-induced stresses and normal oocyte function, practical application of vitrification-warming of oocytes, and potential future directions will be discussed. In addition, we debate commonly discussed technical methods of oocyte vitrification-warming that may not necessarily be grounded in scientific knowledge. Instead these methodologies are many times theoretical, potentially empirical and commonly lack significant testing and scientific rigor. Questions include: (i) what is the best cryoprotectant? (ii) are some cryoprotectants more toxic compared with others? (iii) how should cryosolutions be mixed with cells? (iv) is there a best container for vitrification? (v) is there a threshold cooling-warming rate or is a faster rate always better? and finally (vi) should oocytes be vitrified with or without adjacent cells? With this said, it is recognized that important advancements have been made in the past decade in oocyte cryopreservation, many times through empirical findings. Finally, we propose some new areas of research that may influence future success of oocyte vitrification and warming, fully recognizing that these theories require mechanical and biological experimental testing.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21763203     DOI: 10.1016/j.rbmo.2011.05.003

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  13 in total

1.  Oocyte morphology does not affect post-warming survival rate in an egg-cryobanking donation program.

Authors:  Amanda Souza Setti; Rita de Cássia Savio Figueira; Daniela Paes de Almeida Ferreira Braga; Renata Cristina Ferreira; Assumpto Iaconelli; Edson Borges
Journal:  J Assist Reprod Genet       Date:  2011-12-04       Impact factor: 3.412

Review 2.  Oocyte cryopreservation: searching for novel improvement strategies.

Authors:  Natalie A Clark; Jason E Swain
Journal:  J Assist Reprod Genet       Date:  2013-06-19       Impact factor: 3.412

3.  Survival and post-warming in vitro competence of human oocytes after high security closed system vitrification.

Authors:  N De Munck; G Verheyen; L Van Landuyt; D Stoop; H Van de Velde
Journal:  J Assist Reprod Genet       Date:  2013-01-25       Impact factor: 3.412

4.  Live birth after 6 years of oocyte vitrification in a survivor with breast cancer.

Authors:  Eduardo Leme Alves da Motta; Monique Bonavita; José Roberto Alegretti; Maurício Chehin; Paulo Serafini
Journal:  J Assist Reprod Genet       Date:  2014-08-22       Impact factor: 3.412

5.  Slow and steady cell shrinkage reduces osmotic stress in bovine and murine oocyte and zygote vitrification.

Authors:  D Lai; J Ding; G W Smith; G D Smith; S Takayama
Journal:  Hum Reprod       Date:  2014-10-29       Impact factor: 6.918

6.  Toward theoretical understanding of the fertility preservation decision-making process: examining information processing among young women with cancer.

Authors:  Patricia E Hershberger; Lorna Finnegan; Susan Altfeld; Sara Lake; Jennifer Hirshfeld-Cytron
Journal:  Res Theory Nurs Pract       Date:  2013       Impact factor: 0.688

Review 7.  Ultrastructure of human mature oocytes after vitrification.

Authors:  M A Khalili; M Maione; M G Palmerini; S Bianchi; G Macchiarelli; S A Nottola
Journal:  Eur J Histochem       Date:  2012-08-10       Impact factor: 3.188

8.  Mouse oocyte vitrification with and without dimethyl sulfoxide: influence on cryo-survival, development, and maternal imprinted gene expression.

Authors:  Clementina Cantatore; Jenny S George; Raffaella Depalo; Giuseppe D'Amato; Molly Moravek; Gary D Smith
Journal:  J Assist Reprod Genet       Date:  2021-05-22       Impact factor: 3.357

Review 9.  Postponing Pregnancy Through Oocyte Cryopreservation for Social Reasons: Considerations Regarding Clinical Practice and the Socio-Psychological and Bioethical Issues Involved.

Authors:  Mara Simopoulou; Konstantinos Sfakianoudis; Panagiotis Bakas; Polina Giannelou; Christina Papapetrou; Theodoros Kalampokas; Anna Rapani; Ekaterini Chatzaki; Maria Lambropoulou; Chrysoula Lourida; Efthymios Deligeoroglou; Konstantinos Pantos; Michael Koutsilieris
Journal:  Medicina (Kaunas)       Date:  2018-10-25       Impact factor: 2.430

10.  Optimized protocol for cryopreservation of human eggs improves developmental competence and implantation of resulting embryos.

Authors:  Cassie T Wang; Lifeng Liang; Craig Witz; Dan Williams; Jason Griffith; Josh Skorupski; Ghassan Haddad; Jimmy Gill; Weihua Wang
Journal:  J Ovarian Res       Date:  2013-02-13       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.